Boston Scientific now expects to close its $14.5 billion acquisition of Penumbra in early 2027. The original plan was to close in 2026. CEO Mike Mahoney told analysts on October 28 that the regulatory process has taken a bit of time, and said the company remains confident in closing.
The agreement, announced January 15, 2026, pays $374 per Penumbra share in a mix of cash and stock. Penumbra booked about $1.4 billion of revenue in 2025 selling mechanical thrombectomy systems used in pulmonary embolism, stroke and deep vein thrombosis, plus an embolization system. It picked up a DVT indication for its Lightning computer-assisted vacuum thrombectomy technology on October 22.
The slip landed in the company's worst quarter of the year. Third quarter revenue rose 1.5 percent to $5.14 billion and net income fell to $582 million from $755 million. Watchman sales dropped 6 percent after growing almost 30 percent in 2025, electrophysiology dropped 5 percent under pulsed field ablation competition, and full year revenue growth guidance came down to 4.25 percent against a February forecast of 10.5 to 11.5 percent.
Mahoney guided 2027 with a carve-out, saying the company will be challenged to grow sales and adjusted EPS next year excluding the pending Penumbra deal. That phrasing puts a good share of the 2027 growth story on a transaction that has not finished review.